According to data from a press release, which were later presented at the EULAR 2021 Virtual Congress, “Anifrolumab was consistently associated with improvements in both skin rash and arthritis across three different disease measures…in patients with moderate to severe SLE.”
In study findings presented at the EULAR 2021 Virtual Congress, researchers compared the efficacy between tofacitinib and baricitinib in patients with RA in clinical practice.
Researchers assessed the incidence of heart failure in patients with incident rheumatoid arthritis and compared it with those without RA.
In a study presented at EULAR 2021 Virtual Congress, researchers evaluated the effect of mavrilimumab on clinical outcomes in patients hospitalized with severe COVID-19 pneumonia and systemic hyperinflammation.
Researchers determined the prevalence VEXAS in patients with relapsing polychondritis, assessed clinical, laboratory, and immunologic features, and developed a clinical algorithm to inform genetic screening for VEXAS in this population.
In a study presented at the EULAR 2021 Virtual Congress, researchers evaluated the safety and efficacy of intravenous immunoglobulin therapy in adult patients with dermatomyositis.
Using the CORRONA (now CorEvitas) PsA/SpA Registry, study authors compared the characteristics of patients with axial psoriatic arthritis and axial spondyloarthritis.
In this study presented at the EULAR 2021 Virtual Congress, researchers examined the demographics and comorbidities of patients with uncontrolled gout receiving pegloticase.
In a study presented at the EULAR 2021 Virtual Congress, researchers evaluated the safety and efficacy of guselkumab in patients with psoriatic arthritis with an inadequate response to TNF inhibition.